ISSN 2398-2942      

Lymphoma: chemotherapy protocols

icanis

Synonym(s): Lymphosarcoma: chemotherapy protocols


Introduction

  • The following chemotherapy protocols for lymphoma will be covered:
    • Induction protocols:
      • Modified UW-Madison (UW 25) (CHOP-based).
      • Modified LOPP.
      • Combination cytotoxic therapy COP.
      • Single - agent doxorubicin.
      • Single-agent rabacfosadine.
    • Rescue protocols:
      • CCNU + prednisolone.
      • L-asparaginase +CCNU+ prednisolone.
      • DMAC protocol.
Do not use without consulting specialist oncologist.Refer to chemotherapy safety administration Chemotherapy: safe handling.

Protocol 1: Modified UW-Madison (UW 25) (CHOP-based)

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Protocol 2: modified LOPP

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Protocol 3: Combination cytotoxic therapy COP

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Protocol 4: Single-agent doxorubicin

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Protocol 5: Single-agent rabacfosadine

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Rescue protocols

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Legal and safety precautions

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Saba C F, Clifford C, Burgess K, Phillips B, Vail D, Wright Z, Curran K, Fan T, Elmslie R, Post G, Thamm D (2020) Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Vet Comp Oncol Apr 28 PubMed.
  • Smallwood K, Tanis J B, Grant I A, Blackwood L, Killick D R, Amores-Fuster I, Elliott J, Mas A, Harper A, Marrington M, Finotello R (2019) Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience. Vet Comp Oncol 17(2),165-173 PubMed
  • Saba C F, Vickery K R, Clifford C A, Burgess K E, Phillips B, Vail D M, Wright Z M, Morges M A, Fan T M, Thamm D H (2018) Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Vet Comp Oncol 16(1), E76-E82 PubMed.
  • Morgan E, O'Connell K, Thomson M, Griffin A (2018) Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs. Vet Comp Oncol 16(4), 622-629 PubMed
  • Brown P M, Tzannes S, Nguyen S, White J, Langova V (2018) LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. Vet Comp Oncol 16(1), 108-113 PubMed
  • Thamm D H, Vail D M, Post G S, Fan T M, Phillips B S et al (2017) Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naıve Canine Multicentric Lymphoma. J Vet Intern Med 31(3), 872-878 PubMed.
  • Parsons-Doherty M, Poirier V J, Monteith G (2014) The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma. Can Vet J 55(2),175-180 PubMed.
  • Fahey C E, Milner R J, Barabas K, Lurie D, Kow K, Parfitt S, Lyles S, Clemente M (2011) Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). J Am Vet Med Assoc 239(2), 209-215 PubMed.
  • Vail D M , Thamm D H, Reiser H, Ray A S, Wolfgang G H I (2009) Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma. Clin Cancer Res 15 (10), 3503-3510 PubMed.
  • Saba C F, Thamm D H, Vail D M (2007) Combination chemotherapy with L-asparginase, lomustine and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med 21 (1), 127-131 PubMed.
  • Simon D, Nolte I, Eberle N et al (2006) Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 20 (4), 948-954 PubMed.
  • Alvarez F J, Kisseberth, W C, Gallant S L, Couto C G (2006) Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma. J Vet Intern Med 20(5), 1178-1183 PubMed.
  • MacDonald V S, Thamm D H, Kurzman I D et al (2005) Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 19 (5), 732-736 PubMed.
  • Jeffreys A B, Knapp D W, Carlton W W et al (2005) Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. JAAHA 41 (4), 221-226 PubMed.
  • Vail D M & Thamm D H (2005) Cytotoxic chemotherapy: new players, new tacticsJAAHA 41 (4), 209-214 PubMed.
  • Kristal O, Rassnick K M, Gliatto J M et al (2004) Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 18 (1), 75-80 PubMed.
  • Brønden LB, Rutteman G R, Flagstad A et al (2003) Study of dog and cat owners' perceptions of medical treatment for cancer. Vet Rec 152 (3), 77-80 PubMed.
  • Charney S C, Bergman P J, Hohenhaus A E et al (2003) Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). JAVMA 222 (10), 1388-1393 PubMed.
  • Garrett L D, Thamm D H, Chun R et al (2002) Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 16 (6), 704-709 PubMed.
  • Rassnick K M, Mauldin G E, Al-Sarraf R et al (2002) MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). JVIM 16 (5), 576-580 PubMed.
  • Moore A S, Cotter S M, Rand W M et al (2001) Evaluation of a continuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 15 (4), 348-354 PubMed.
  • Boyce K L & Kitchell B E (2000) Treatment of canine lymphoma with COPLA/LVP. JAAHA 36 (5), 395-403 PubMed.
  • Chun R, Garrett L D & Vail D M (2000) Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 14 (2), 120-124 PubMed.
  • Piek C J, Rutteman G R & Teske E (1999) Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Vet Q 21 (2), 44-49 PubMed.
  • Myers N C 3rd, Moore A S, Rand W M et al (1997) Evaluation of a multi-drug chemotherapy protocol (ACOPA 11) in dogs with lymphoma. J Vet Intern Med 11 (6), 333-339 PubMed.
  • Valerius K D, Oglivie G K, Mallinckrodt C H et al (1997) Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). JAVMA 210 (4), 512-516 PubMed.

Other sources of information

  • Vail D M, Pinkerton M E, Young K M (2020) Canine lymphoma and lymphoid leukemias. In: Small animal clinical oncology. 6th edn. Eds Withrow & MacEwen’s. Elsevier Saunders, St. Louis. pp 688-715. 
  • Tennant B (2002) BSAVA Small Animal Formulary, 4th edn. pp 280-281.

Can’t find what you’re looking for?

We have an ever growing content library on Vetlexicon so if you ever find we haven't covered something that you need please fill in the form below and let us know!